Breast tumour angiogenesis

被引：131

作者：

Fox, Stephen B. ^{[1
]}

Generali, Daniele G. ^{[2
]}

Harris, Adrian L. ^{[3
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia

[2] Ist Ospitalieri Cremona, Senol & Breast Canc Unit, Unit Patol Mammaria, I-26100 Cremona, Italy

[3] John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK, Oxford OX3 9DS, England

来源：

BREAST CANCER RESEARCH | 2007年 / 9卷 / 06期

关键词：

D O I：

10.1186/bcr1796

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The central importance of tumour neovascularization has been emphasized by clinical trials using antiangiogenic therapy in breast cancer. This review gives a background to breast tumour neovascularization in in situ and invasive breast cancer, outlines the mechanisms by which this is achieved and discusses the influence of the microenvironment, focusing on hypoxia. The regulation of angiogenesis and the antivascular agents that are used in an antiangiogenic dosing schedule, both novel and conventional, are also summarized.

引用

页数：11

共 140 条

[1] Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways [J].

Arbiser, JL ;

Moses, MA ;

Fernandez, CA ;

Ghiso, N ;

Cao, YH ;

Klauber, N ;

Frank, D ;

Brownlee, M ;

Flynn, E ;

Parangi, S ;

Byers, HR ;

Folkman, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) :861-866

[2] Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization [J].

Asahara, T ;

Masuda, H ;

Takahashi, T ;

Kalka, C ;

Pastore, C ;

Silver, M ;

Kearne, M ;

Magner, M ;

Isner, JM .

CIRCULATION RESEARCH, 1999, 85 (03) :221-228

[3] VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells [J].

Asahara, T ;

Takahashi, T ;

Masuda, H ;

Kalka, C ;

Chen, DH ;

Iwaguro, H ;

Inai, Y ;

Silver, M ;

Isner, JM .

EMBO JOURNAL, 1999, 18 (14) :3964-3972

[4] Update on clinical trials targeting vascular endothelial growth factor in cancer [J].

Bergsland, EK .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (21) :S12-S20

[5] Neuropilins in neoplasms: Expression, regulation, and function [J].

Bielenberg, DR ;

Pettaway, CA ;

Takashima, S ;

Klagsbrun, M .

EXPERIMENTAL CELL RESEARCH, 2006, 312 (05) :584-593

[6] Beyond anaemia management: Evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models [J].

Boogaerts, M ;

Mittelman, M ;

Vaupel, P .

ONCOLOGY, 2005, 69 :22-30

[7] Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma [J].

Bos, R ;

van der Groep, P ;

Greijer, AE ;

Shvarts, A ;

Meijer, S ;

Pinedo, HM ;

Semenza, GL ;

van Diest, PJ ;

van der Wall, E .

CANCER, 2003, 97 (06) :1573-1581

[8] Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients [J].

Bottini, Alberto ;

Generali, Daniele ;

Brizzi, Maria Pia ;

Fox, Stephen B. ;

Bersiga, Alessandro ;

Bonardi, Simone ;

Allevi, Giovanni ;

Aguggini, Sergio ;

Bodini, Giuliana ;

Milani, Manuela ;

Dionisio, Rossana ;

Bernardi, Claudio ;

Montruccoli, Arianna ;

Bruzzi, Paolo ;

Harris, Adrian L. ;

Dogliotti, Luigi ;

Berruti, Alfredo .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) :3623-3628

[9] Glomeruloid microvascular proliferation orchestrated by VPF/VEGF - A new world of angiogenesis research [J].

Brat, DJ ;

Van Meir, EG .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (03) :789-796

[10]

BREM SS, 1978, CANCER, V41, P239, DOI 10.1002/1097-0142(197801)41:1<239::AID-CNCR2820410133>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →